Omnicell (NASDAQ:OMCL) was downgraded by research analysts at Craig Hallum from a “buy” rating to a “hold” rating in a report issued on Friday, The Fly reports.
OMCL has been the subject of several other reports. Cantor Fitzgerald upped their price objective on Omnicell to $58.00 and gave the stock an “overweight” rating in a research report on Friday, October 27th. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. BidaskClub downgraded Omnicell from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Finally, Oppenheimer restated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $56.14.
Shares of Omnicell (NASDAQ OMCL) traded down $2.90 during mid-day trading on Friday, hitting $46.00. The company had a trading volume of 1,532,901 shares, compared to its average volume of 210,467. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Omnicell has a twelve month low of $35.00 and a twelve month high of $55.40. The company has a market cap of $1,740.00, a P/E ratio of -418.18, a P/E/G ratio of 3.89 and a beta of 0.65.
In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the transaction, the chief financial officer now directly owns 40,544 shares in the company, valued at $2,095,719.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter J. Kuipers sold 4,724 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $47.74, for a total value of $225,523.76. Following the completion of the transaction, the vice president now owns 40,544 shares of the company’s stock, valued at $1,935,570.56. The disclosure for this sale can be found here. Insiders sold 27,558 shares of company stock valued at $1,330,230 over the last quarter. Corporate insiders own 3.77% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Comerica Bank raised its position in Omnicell by 27.1% in the fourth quarter. Comerica Bank now owns 97,386 shares of the company’s stock valued at $4,972,000 after purchasing an additional 20,754 shares during the last quarter. Mesirow Financial Investment Management Equity Management raised its position in Omnicell by 10.0% in the fourth quarter. Mesirow Financial Investment Management Equity Management now owns 425,647 shares of the company’s stock valued at $20,645,000 after purchasing an additional 38,605 shares during the last quarter. Braun Stacey Associates Inc. bought a new position in Omnicell in the fourth quarter valued at about $9,391,000. Fisher Asset Management LLC increased its stake in shares of Omnicell by 0.3% in the fourth quarter. Fisher Asset Management LLC now owns 530,569 shares of the company’s stock valued at $25,733,000 after buying an additional 1,650 shares during the period. Finally, Strs Ohio increased its stake in shares of Omnicell by 7.7% in the fourth quarter. Strs Ohio now owns 70,000 shares of the company’s stock valued at $3,395,000 after buying an additional 5,000 shares during the period.
TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/02/craig-hallum-downgrades-omnicell-omcl-to-hold.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.